Primary myelofibrosis: current therapeutic options
AUTOR(ES)
Campos, Paula de Melo
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2016-09
RESUMO
ABSTRACT Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure. Clonal evolution can also occur, with an increased risk of transformation to acute myeloid leukemia. In addition, disabling constitutional symptoms secondary to the high circulating levels of proinflammatory cytokines and hepatosplenomegaly frequently impair quality of life. Herein the main current treatment options for primary myelofibrosis patients are discussed, contemplating disease-modifying therapeutics in addition to palliative measures, in an individualized patient-based approach.
Documentos Relacionados
- Myelofibrosis: Pathophysiology and Clinical Management
- Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
- Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor
- Pathogenesis of idiopathic myelofibrosis: role of growth factors.
- Therapeutic options for ectopic pregnancy.
